日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

伊布替尼-利妥昔单抗联合化疗免疫疗法治疗慢性淋巴细胞白血病的长期疗效:E1912试验的最新结果

Shanafelt, Tait D; Wang, Xin Victoria; Hanson, Curtis A; Paietta, Elisabeth M; O'Brien, Susan; Barrientos, Jacqueline; Jelinek, Diane F; Braggio, Esteban; Leis, Jose F; Zhang, Cong Christine; Coutre, Steven E; Barr, Paul M; Cashen, Amanda F; Mato, Anthony R; Singh, Avina K; Mullane, Michael P; Little, Richard F; Erba, Harry; Stone, Richard M; Litzow, Mark; Tallman, Martin; Kay, Neil E

Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study

伊布替尼治疗重症冠状病毒病2019感染住院成人患者:随机、双盲、安慰剂对照iNSPIRE研究结果

Coutre, Steven E; Barnett, Christopher; Osiyemi, Olayemi; Hoda, Daanish; Ramgopal, Moti; Fort, Alexander C; Qaqish, Roula; Hu, Yiran; Ninomoto, Joi; Alami, Negar N; Styles, Lori; Treon, Steven P

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.

可测量的残留病灶并不妨碍接受伊布替尼治疗的慢性淋巴细胞白血病患者获得较长的无进展生存期

Wang Xin Victoria, Hanson Curtis A, Tschumper Renee C, Lesnick Connie E, Braggio Esteban, Paietta Elisabeth M, O'Brien Susan, Barrientos Jacqueline C, Leis Jose Francisco, Zhang Cong Christine, Coutre Steven E, Barr Paul M, Cashen Amanda F, Mato Anthony R, Singh Avina K, Mullane Michael P, Erba Harry, Stone Richard, Litzow Mark R, Tallman Martin S, Shanafelt Tait D, Kay Neil E

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

伊布替尼治疗一线及复发/难治性慢性淋巴细胞白血病:关键性 Ib/II 期 PCYC-1102 研究的最终分析

Byrd, John C; Furman, Richard R; Coutre, Steven E; Flinn, Ian W; Burger, Jan A; Blum, Kristie; Sharman, Jeff P; Wierda, William; Zhao, Weiqiang; Heerema, Nyla A; Luan, Ying; Liu, Emily A; Dean, James P; O'Brien, Susan

Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial

一项 III 期随机试验评估了 idelalisib 对复发性慢性淋巴细胞白血病患者健康相关生活质量的影响

Ghia, Paolo; Coutre, Steven E; Cheson, Bruce D; Barrientos, Jacqueline C; Hillmen, Peter; Pettitt, Andrew R; Zelenetz, Andrew D; Shreay, Sanatan; Hallek, Michael; Furman, Richard R

A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)

ATRA、三氧化二砷和吉妥珠单抗奥佐米星治疗高危 APL 患者的 II 期研究 (SWOG 0535)

Lancet, Jeffrey E; Moseley, Anna B; Coutre, Steven E; DeAngelo, Daniel J; Othus, Megan; Tallman, Martin S; Litzow, Mark R; Komrokji, Rami S; Erba, Harry P; Appelbaum, Frederick R

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

一项随机、III期研究的最终结果:利妥昔单抗联合或不联合伊德拉利西布治疗复发性慢性淋巴细胞白血病患者,随后进行开放标签伊德拉利西布治疗。

Sharman, Jeff P; Coutre, Steven E; Furman, Richard R; Cheson, Bruce D; Pagel, John M; Hillmen, Peter; Barrientos, Jacqueline C; Zelenetz, Andrew D; Kipps, Thomas J; Flinn, Ian W; Ghia, Paolo; Eradat, Herbert; Ervin, Thomas; Lamanna, Nicole; Coiffier, Bertrand; Pettitt, Andrew R; Ma, Shuo; Tausch, Eugen; Cramer, Paula; Huang, Julie; Mitra, Siddhartha; Hallek, Michael; O'Brien, Susan M; Stilgenbauer, Stephan

Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy

正电子发射断层扫描-计算机断层扫描在接受B细胞受体通路抑制剂治疗的慢性淋巴细胞白血病患者中的应用价值

Mato, Anthony R; Wierda, William G; Davids, Matthew S; Cheson, Bruce D; Coutre, Steven E; Choi, Michael; Furman, Richard R; Heffner, Leonard; Barr, Paul M; Eradat, Herbert; Ford, Sharanya M; Zhou, Lang; Verdugo, Maria; Humerickhouse, Rod A; Potluri, Jalaja; Byrd, John C

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis

接受伊布替尼治疗的患者发生大出血的概率和危险因素:一项综合分析

Brown, Jennifer R; Moslehi, Javid; Ewer, Michael S; O'Brien, Susan M; Ghia, Paolo; Cymbalista, Florence; Shanafelt, Tait D; Fraser, Graeme; Rule, Simon; Coutre, Steven E; Dilhuydy, Marie-Sarah; Cramer, Paula; Jaeger, Ulrich; Dreyling, Martin; Byrd, John C; Treon, Steven; Liu, Emily Y; Chang, Stephen; Bista, Amulya; Vempati, Rama; Boornazian, Lisa; Valentino, Rudolph; Reddy, Vijay; Mahler, Michelle; Yang, Huiying; Graef, Thorsten; Burger, Jan A

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials

慢性淋巴细胞白血病患者对伊布替尼完全缓解的预后因素:两项临床试验的汇总分析

O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C; Bannerji, Rajat; Blum, Kristie A; Fox, Christopher P; Furman, Richard R; Hillmen, Peter; Kipps, Thomas J; Montillo, Marco; Sharman, Jeff; Suzuki, Sam; James, Danelle F; Chu, Alvina D; Coutre, Steven E